June 3, 2020
FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
FDA allowed FSD Pharma to submit an Investigational New Drug Application (IND) for the use of FSD-201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.